Wanbangde Pharmaceutical Holding Group Co Ltd (002082) — Strategic Asset Allocation Index
Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has a Strategic Asset Allocation Index of 51.4% as of June 2023. Strategic assets (PP&E of CN¥1.42 Billion plus long-term investments of CN¥-) total CN¥1.42 Billion, measured against net assets of CN¥2.77 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check 002082 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Wanbangde Pharmaceutical Holding Group Co Ltd Strategic Asset Allocation Index (2003–2021)
This chart shows how Wanbangde Pharmaceutical Holding Group Co Ltd's Strategic Asset Allocation Index has evolved across 19 annual periods from 2003 to 2021. As of June 2023, the index stands at 51.4%, representing strategic assets of CN¥1.42 Billion against net assets of CN¥2.77 Billion CNY. See 002082 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2021, covering 19 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market cap of Wanbangde Pharmaceutical Holding Group C.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 42.8% | CN¥1.18 Billion | CN¥1.18 Billion | CN¥- | CN¥2.74 Billion | ▼ -18.0 pp |
| 2020 | 60.8% | CN¥1.74 Billion | CN¥1.74 Billion | CN¥- | CN¥2.86 Billion | ▼ -3.7 pp |
| 2019 | 64.5% | CN¥1.23 Billion | CN¥1.23 Billion | CN¥- | CN¥1.91 Billion | ▲ +48.4 pp |
| 2018 | 16.2% | CN¥278.60 Million | CN¥278.60 Million | CN¥- | CN¥1.72 Billion | ▼ -15.6 pp |
| 2017 | 31.8% | CN¥509.95 Million | CN¥509.95 Million | CN¥- | CN¥1.60 Billion | ▲ +2.9 pp |
| 2016 | 28.9% | CN¥403.55 Million | CN¥403.55 Million | CN¥- | CN¥1.40 Billion | ▼ -4.6 pp |
| 2015 | 33.5% | CN¥451.11 Million | CN¥451.11 Million | CN¥- | CN¥1.35 Billion | ▼ -2.2 pp |
| 2014 | 35.7% | CN¥462.27 Million | CN¥462.27 Million | CN¥- | CN¥1.30 Billion | ▼ -9.3 pp |
| 2013 | 45.0% | CN¥534.18 Million | CN¥534.18 Million | CN¥- | CN¥1.19 Billion | ▼ -10.0 pp |
| 2012 | 55.0% | CN¥603.37 Million | CN¥603.37 Million | CN¥- | CN¥1.10 Billion | ▼ -3.7 pp |
| 2011 | 58.7% | CN¥618.82 Million | CN¥618.82 Million | CN¥- | CN¥1.05 Billion | ▼ -0.6 pp |
| 2010 | 59.3% | CN¥555.12 Million | CN¥555.12 Million | CN¥- | CN¥936.13 Million | ▼ -13.2 pp |
| 2009 | 72.5% | CN¥588.26 Million | CN¥588.26 Million | CN¥- | CN¥811.59 Million | ▼ -6.7 pp |
| 2008 | 79.2% | CN¥563.86 Million | CN¥563.86 Million | CN¥- | CN¥712.31 Million | ▼ -28.9 pp |
| 2007 | 108.1% | CN¥448.58 Million | CN¥448.58 Million | CN¥- | CN¥415.12 Million | ▲ +9.8 pp |
| 2006 | 98.3% | CN¥351.63 Million | CN¥351.63 Million | CN¥- | CN¥357.72 Million | ▼ -103.2 pp |
| 2005 | 201.5% | CN¥308.10 Million | CN¥308.10 Million | CN¥- | CN¥152.88 Million | ▲ +33.5 pp |
| 2004 | 168.0% | CN¥228.80 Million | CN¥228.80 Million | CN¥- | CN¥136.17 Million | ▲ +29.2 pp |
| 2003 | 138.8% | CN¥136.77 Million | CN¥136.77 Million | CN¥- | CN¥98.53 Million | — |